Appropriate interruption of cetuximab may balance efficacy and toxicity: a case of long-term treatment with FOLFIRI plus cetuximab

DOI Web Site 5 References Open Access
  • Matsui Takanori
    Department of gastroenterological surgery, Aichi cancer center Aichi hospital
  • Kojima Hiroshi
    Department of gastroenterological surgery, Aichi cancer center Aichi hospital
  • Fujii Yuka
    Certified nurse in wound, ostomy and continence nursing, Aichi cancer center Aichi hospital
  • Yamada Tomohiro
    Department of gastroenterological surgery, Aichi cancer center Aichi hospital
  • Hirota Masashi
    Department of gastroenterological surgery, Aichi cancer center Aichi hospital
  • Uemura Takanori
    Department of gastroenterological surgery, Aichi cancer center Aichi hospital
  • Fujimitsu Yasunobu
    Department of gastroenterological surgery, Aichi cancer center Aichi hospital
  • Sakamoto Junichi
    Department of Social-Life Science, Nagoya University Graduate School of Medicine

Bibliographic Information

Published
2010
DOI
  • 10.4993/acrt.18.73
Publisher
The Japanese Society of Strategies for Cancer Research and Therapy

Search this article

Description

A case of long-term treatment with FOLFIRI plus cetuximab was presented. A 77-year-old Japanese male was introduced FOLFIRI plus cetuximab as second line treatment. Although the CT revealed partial response, dermatologic adverse event was rather severe and eventually the case required cetuximab cessation. During the FOLFIRI without cetuximab period, CT evaluation revealed disease progression, but after the re-introduction of cetuximab, partial response was observed again. The course of this case would suggest the importance of appropriate cessation of cetuximab in order to balance the efficacy and toxicity, resulting in long treatment period like OPTIMOX strategy.

Journal

References(5)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top